Cynata Therapeutics Ltd has released a press release.
Cynata MSCs beneficial in preclinical ARDS study
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
Story so far
Earlier from Cynata Therapeutics
- Cynata provides guidance on planned clinical trials
- Market Update & Additional A$618k R&D Tax Refund
- Notice of Allowance from Israel Patent Office
- December 2019 Quarterly Report
- Cynata Therapeutics: UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
Later from Cynata Therapeutics
- Cynata announces $5.55m capital raising
- Share Purchase Plan Booklet
- Ethics Approval to Commence Clinical Trial in COVID-19
- Cynata Successfully Completes Share Purchase Plan
- Block Trade Proceeds to Reduce Director Loans
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics